Objective To investigate the interference role that two kinds of adipokines,adiponectin and leptin,exert to hepatocellular apoptosis in mice with acute liver injury induced by Concanavalin A(ConA).MethodsTwenty-six male BALB/c mice were divided into four groups randomly:ConA group(8 mice),adiponectin group(5 mice),leptin group(5 mice) and control group(8 mice).Mice were sacrificed 8 hours after ConA-treatment for observing hepatic injury and hepatocellular apoptosis.Results Comparison to ConA group,the mice in adiponectin group showed less hepatic injury and lower ALT level and less hepatocellular apoptosis(P

Objective To investigate the clinical features, risk factors, diagnose, treatments and prognosis of patients with hepatitis B virus (HBV)-related liver failure complicated with invasive pulmonary aspergillosis (IPA). Methods A case-control study was performed to retrospectively analyze the clinical data of 43 patients with HBV-related liver failure complicated with IPA. A cohort of 43 patients with HBV-related liver failure complicated with bacterial infection only was analyzed at the same time and another cohort of 43 patients with HBV-related liver failure without any infections served as the control group. Results Compared with the control group, patients with infection had lower platelet counts and prothrombin activity, higher scores of model for end-stage liver disease (MELD), especially the patients with IPA (F=42.43,13.69,14, 22, all P＜0.01). And the similar results were observed in patients with IPA group before and after Aspergillus infection (F= 12.09,14.52,-16.74, all P＜0.01). Furthermore, the annual mortality was 100. 0% in patients with IPA,which was higher than that of patients complicated with bacterial infection only; and both groups were higher than control group of patients without infection. The statistic results showed that patients with longer length of stay, more antibiotics usage, and more invasive procedures were all risk factors of HBV-related liver failure complicated with IPA. Conclusions Conditions of patients with HBV-related liver failure deteriorate rapidly after complicated with IPA and patients have higher mortality and poorer prognosis.Therefore, it will be effective to enhance the recognition of the early clinical manifestations, and make diagnosis timely and treat with potent anti-fungal therapy to improve their survival.

Objective To evaluate the short-term and long-term survival rate for Entecavir versus Lamivudine in the treatment of patients with HBV-related liver failure through Meta-analysis.Methods Relevant literature published from 2007 to 2015 in Chinese or English were searched,papers fully matching the inclusion criteria were brought into the study.RavMan 5.2 statistical software was utilized for Meta-analysis.The survival rate of 4-week,12-week,24-week,48-week were analyzed by forest plot.Results Total 1837 patients from 18 controlled clinical trials reported in Chinese and English were recruited in this study,which involving survival rate for Entecavir versus Lamivudine in the treatment of patients with HBV-related liver failure.Among them 12 papers were cohort and 6 were RCT(Randomized Controlled Trial) study.Meta analysis show:HBV DNA undetectable rate of 4-week、12-week、24-week and 48-week in Entecavir group were higher than that in Lamivudine group (4-week:RR =1.52,Z =4.11,P ＜ 0.01;12-week:RR =1.26,Z =3.85,P ＜0.01;24-week:RR =1.26,Z =5.16,P ＜0.01;48-week:RR =1.22,Z =3.41,P ＜ 0.01),survival rate of four-week,twelve-week,twenty four-week had no significant differences between Entecavir and Lamivudine group (4-week:RR =0.97,Z =0.55,P =0.58;12-week:RR =1.01,Z =0.15,P =0.88;24-week:RR =1.02,Z =0.56,P =0.57),fourty eight-week survival rate in Entecavir group was higher than that in Lamivudine group(48-week:RR =1.18,Z =2.84,P ＜ 0.01).Conclusions The data indicated that Entecavir was more effective in the management of HBV levels and better improve the long-term prognosis of patients with HBV-associated liver failure than Lamivudine,which might be more suitable for long-term treatment to patients with HBV-related liver failure.